Gilead, MicroDose Enter RSV Pact

Gilead Sciences and MicroDose Therapeutx have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

MicroDose will receive an upfront payment and research funding to support development of MDT-637 through Phase IIa trials, after which Gilead can assume full development responsibility. MicroDose is also eligible to receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as development fees and royalties on potential sales.

“This strategic collaboration is a significant milestone in MicroDose’s vision to develop first-in-class therapies for major unmet medical needs,” said Anand Gumaste, president and chief executive officer of MicroDose. “Given Gilead’s scientific and clinical expertise in virology, this partnership provides a strong validation of the potential for MDT-637 to become an important therapeutic advance for those affected by RSV infection.”

“There is an urgent need to improve upon RSV treatment and care,” said Norbert W. Bischofberger, Ph.D., Gilead’s executive vice president, R&D and chief scientific officer. “We believe this program aligns well with our expertise in both antiviral and respiratory drug development and we look forward to working with the MicroDose team to advance MDT-637 into clinical testing.”